Aileron Therapeutics
Presença
Aileron Therapeutics é uma empresa listada sob o símbolo ALRN (US).
Fusão, aquisição e financiamento envolvendo Aileron Therapeutics.
Executivos
Veja o organograma con seus 8 executivos principais
Biografias mais buscadas da Aileron Therapeutics
- Brian Windsor, Director, President and Chief Executive Officer
- Reinhard Ambros, Director
- Manuel Aivado, Director
Recentes movimentos de executivos em Aileron Therapeutics
- Brian Windsor antes Chief Operating Officer and President, foi promovido a Director, President and Chief Executive Officer (Notícia publicada em 13 de março de 2024).
Criar um alerta
para seguir os movimentos de executivos da Aileron Therapeutics.
Biotecnologia
Aileron Therapeutics possui 2.293 concorrentes concorrentes Lonza (Suíça), Eurofins (Luxemburgo) e Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnologia
- Merck has announced the acquisition of EyeBio (publicado em 31 de maio de 2024).
- Actuate Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 29 de maio de 2024).
- Grey Wolf Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 25 de maio de 2024).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Aileron Therapeutics
- Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer ― Aileron
- Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022 ― Aileron
- Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer ― Aileron
- Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer ― Aileron Therapeutics
- Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference ― Aileron Therapeutics
- Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022 ― Aileron Therapeutics
- Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual
- Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights ― Aileron Therapeutics
- Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights ― Aileron Therapeutics
- Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference ― Aileron Therapeutics
- View more press releases Close
Redes sociais sobre Aileron Therapeutics
- Aileron Therapeutics na Wikipedia, Google News e Yahoo Finance
- Aileron Therapeutics na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Manuel Aivado 
Ligue para a Aileron Therapeutics em +1 617...
